Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.

Volume: 21, Issue: 5, Pages: 1096 - 1103
Published: May 1, 2013
Abstract
Selective delivery of therapeutic molecules to primary and metastatic tumors is optimal for effective cancer therapy. A liposomal nanodelivery complex (scL) for systemic, tumor-targeting delivery of anticancer therapeutics has been developed. scL employs an anti-transferrin receptor (TfR), scFv as the targeting molecule. Loss of p53 suppressor function, through mutations or inactivation of the p53 pathway, is present in most human cancers....
Paper Details
Title
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.
Published Date
May 1, 2013
Volume
21
Issue
5
Pages
1096 - 1103
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.